Cetuximab in the treatment of metastatic colorectal cancer: A model-based cost-effectiveness analysis

Journal of Chemotherapy

Volumn 18, Issue 5, 2006, Pages 532-537

  Norum, Jan ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Cetuximab; Health economics; Metastatic colorectal cancer

Indexed keywords

CETUXIMAB; IRINOTECAN; ONDANSETRON;

ADULT; AGED; ARTICLE; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDLINE; METASTASIS; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS;

EID: 33751178148     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.5.532     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Int J Cancer 2001; 94: 153-156.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5. Lyon. IARC Press 2001.
3. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
4. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17: 259-269.
5. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magné N, Milano G. Pharmacological backgound of EGFR targeting. Ann Oncol 2004; 15: 1007-1012.
6. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclinal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003.
7. Drummond MF, O'Brian B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford Medical Publications, Third edition. Oxford University Press, Oxford, New York, Toronto 2005.
8. Rubin EH, Doroshow J, Hidalgo M, et al. A study to access the pharmokinetics (PK) of a single infusion of cetuximab (IMC-C225). Proc Am Soc Clin Oncol 2004; 22; a3084.
9. Lenz HJ, Mayer J, Gold J, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004; 22; a3510.
10. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 2004, 22; a3512
11. Badarinath S, Mitchell EP, Jennis A, et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE). Preliminary safety analysis of a randomised phase III trial. Proc Am Soc Clin Oncol 2004; 22; a3531.
12. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 20004; 22; a3513.
13. Mirtsching B, Headlee C, Beasley S, Teel C, Jackson D. Cetuximab single-agent in refractory metastatic colorectal cancer. Single-center experience. Proc Am Soc Clin Oncol 2004; 22: a3703.
14. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: a7.
15. Chow NH, Chan Sh, Tzai TS, Ho CL, Liu HS. Expresion profiles of ErbB family receptors and prognosis in primary transitional cell carcinomas of the urinary bladder. Clin Cancer Res 2001; 7: 1957-1962.
16. Saltz L, Meropol NJ, Lochrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
17. National Insurance Administration, Rikstrygdeverket: [cited 2004 Dec 15]; Available from: URL: http://www.trygdeetaten.no
18. st 2004. Oslo, The National Health Administration, 2003.
19. Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol 1997; 8: 1081-1087.
20. Messa C, Russo F, Caruso MG, DiLeo A. EGF, TGF-alpha and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37: 285-289.
21. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
22. Lenz HJ, Mayer J, Gold J, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004; 22; a3510.
23. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-319.
24. Bazell R. Strange medicine. Why are the new cancer drugs so expensive? MSN. [cited 2005 Jan 23]; Available from: URL: http://slate.msn.com/id/2102844.
25. Chapman RH, Berger M, Weinstein MC, et al. When does quality-adjusting life matters in cost-effectiveness analysis? Health Econ 2004; 13: 429-436.
26. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002 22: 417-430.
27. Nadler ES, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Proc Am Soc Clin Oncol 2005; 23: a6011.
28. Erlichman C, Sargent DJ. New treatment options for colorectal cancer. N Engl J Med 2004; 351: 391-392.
29. Cunningham D, Pyrhonen S, James R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352, 1413-1418.